Production (Stage)
Xilio Therapeutics, Inc.
XLO
$0.8838
-$0.0132-1.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 23.47% | 23.77% | 22.67% | 22.22% | 20.73% |
| Total Depreciation and Amortization | -7.92% | -13.47% | -11.44% | -7.99% | -3.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -18.71% | -14.64% | -8.09% | -4.52% | -9.95% |
| Change in Net Operating Assets | 778.41% | 2,016.83% | 2,370.08% | 858.93% | 938.82% |
| Cash from Operations | 139.17% | 73.22% | 75.96% | 78.31% | 32.78% |
| Capital Expenditure | 81.65% | 92.59% | 96.98% | 98.42% | 82.28% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 81.65% | 92.59% | 96.98% | 98.42% | 82.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 99.67% | 49.91% | 0.29% | -155.22% | -380.48% |
| Issuance of Common Stock | 633.97% | 16,027.72% | 16,406.76% | 17,352.86% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 946.32% | 545.74% | 492.14% | 728.98% | -123.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 193.15% | 114.25% | 102.12% | 99.72% | 30.57% |